NanoViricides Inc. (NNVC)

[changes_iv]

So that's how it happens...

Intercept stock triples on liver disease study
AP

ICPT - Intercept Pharmaceuticals Inc
Sym Last Chg Pct Volume
ICPT 281.26 +208.87 +288.53% 4,971,892

NEW YORK (AP) — Shares of Intercept Pharmaceuticals more than tripled in value Thursday morning after the company stopped a clinical trial of a liver disease drug early, saying there was clear evidence the treatment worked.

Intercept said a data monitoring board recommended it stop the trial because patients who were being treated with its experimental drug, obeticholic acid, were faring better than patients who took a placebo. Intercept is studying the drug as a treatment for nonalcoholic steatohepatitis.

Nonalcoholic steatohepatitis is a type of chronic liver disease caused by excessive fat accumulation in the liver. It causes inflammation that can cause scarring. The scarring can lead to cirrhosis, liver failure, and death.

Shares of Intercept Pharmaceuticals Inc. surged $190.22 to $262.61 in morning trading and reached a high of $305. The stock closed at $72.39 on Wednesday.

The data monitoring board (I pressume FDA) stopped the clinical trial, saying there was clear evidence the treatment worked...kaboom , ICPT goes "hillbilly"!

As nanopatent comments imply, we have the shifting-paradigm of antiviral drugs in NanoViricides, Inc., low-toxicity nanoviricides that destroy viruses, the painful and debilitating symptoms, and all in a matter of hours! KaBOOM, from a multi-million dollar cap to a multi-BILLION dollar cap! Wham, From a $20 pps to $100 pps or $200 pps!!! We get FluCide in and like LEGO pieces we get DengueCide and HIVCide to follow in short order!!!